Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was downgraded by equities research analysts at Citigroup from a “buy” rating to a “neutral” rating in a report issued on Friday, MarketBeat reports. They currently have a $55.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $75.00. Citigroup’s price target suggests a potential upside of 5.93% from the stock’s current price.
BMY has been the topic of a number of other research reports. TD Cowen upped their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. UBS Group upped their price target on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, October 9th. BMO Capital Markets reissued a “market perform” rating and issued a $48.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 23rd. Jefferies Financial Group boosted their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a report on Wednesday, August 28th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $50.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $53.31.
Check Out Our Latest Report on Bristol-Myers Squibb
Bristol-Myers Squibb Stock Down 1.9 %
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The business had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. During the same quarter in the prior year, the business earned $1.75 EPS. Bristol-Myers Squibb’s quarterly revenue was up 8.7% on a year-over-year basis. On average, analysts forecast that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.
Hedge Funds Weigh In On Bristol-Myers Squibb
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ESL Trust Services LLC bought a new position in Bristol-Myers Squibb in the 1st quarter valued at approximately $27,000. LGT Financial Advisors LLC lifted its stake in Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 227 shares during the last quarter. ORG Wealth Partners LLC bought a new position in Bristol-Myers Squibb in the 3rd quarter valued at approximately $34,000. MFA Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the 2nd quarter valued at approximately $39,000. Finally, Beach Investment Counsel Inc. PA acquired a new position in Bristol-Myers Squibb in the 2nd quarter valued at approximately $42,000. Institutional investors own 76.41% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Stories
- Five stocks we like better than Bristol-Myers Squibb
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- How to Invest in Insurance Companies: A Guide
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.